# Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

> **NCT05022342** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 595 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** alpelisib plus fulvestrant

## Key facts

- **NCT ID:** NCT05022342
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2025-02-11
- **Final completion:** 2025-02-11
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022342, "Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05022342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*